Haemonetics (NYSE:HAE) announced today that it has completed its previously announced sale of its whole blood assets to GVS S.p.A.
The sale has a total cash consideration of up to $67.8 million, including $45.3 million upfront after giving effect to certain customary adjustments. The deal also includes $22.5 million in contingent earn-outs over the next four years.
GVS (Bologna, Italy) is a manufacturer of filter technology for healthcare and life sciences. It has now acquired Haemonetics’ portfolio of proprietary whole blood collection, processing and filtration products and services, along with Haemonetics’ manufacturing facility in Covina, California. It also involves related equipment and assets at Haemonetics’ manufacturing facility in Tijuana, Mexico.
This deal comes more than four years after Haemonetics’ sale of its Fajardo, Puerto Rico, manufacturing operations to GVS in 2020. A long-term supply and development agreement between the two companies dates back to that deal, too.
According to Haemonetics, its Blood Center business will continue manufacturing and providing customers with its full line of apheresis solutions for automated blood collection. These include devices and disposable kits for a variety of apheresis collections, including platelets, plasma and red cells, and ensure efficient blood center operations.
Boston-based Haemonetics provides medtech related to blood and plasma component collection, the surgical suite and hospital transfusion services.
